Last checked at 23 Dec 2019 11:15
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Result of General Meeting
and
Total Voting Rights
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that at the General Meeting held earlier today, all resolutions proposed were duly passed unanimously by shareholders. Accordingly, the Company has raised £51.9 million in the Fundraising and has issued and allotted 28,835,173 New Ordinary Shares, conditional only on Admission becoming effective. Admission of the New Ordinary Shares is expected at 8.00 a.m. on 24 December 2019.
Following Admission, the Company's issued ordinary share capital will comprise 150,378,758 Ordinary Shares, of which none are held in treasury. The above figure of 150,378,758 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
A summary of the votes received will be made available on the Group's website at investors.creomedical.com. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 4 December 2019.
Enquiries:
Creo Medical Group plc | investors.creomedical.com |
Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
Cenkos Securities | +44 (0)20 7397 8900 |
Stephen Keys / Cameron MacRitchie (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com